Publications by authors named "S Virdone"
Background: The global impact of the COVID-19 pandemic has prompted the search for strategies to improve outcomes in affected individuals, including those initially managed in outpatient settings. Thromboembolic events have been reported as a concerning complication.
Objectives: The aim of this study was to evaluate efficacy and safety of primary thromboprophylaxis in outpatients with COVID-19.
Article Synopsis
- The study aimed to compare stroke prevention strategies, management of comorbidities, and clinical outcomes in patients with atrial fibrillation (AF) across different healthcare specialties: cardiology, primary care, and others.
- Among 52,011 patients, those in cardiology were more likely to receive non-vitamin K oral anticoagulants (NOACs) compared to those in primary care or other specialties, while comorbidity management was similar across all groups.
- Patients receiving care outside of cardiology faced higher risks for non-cardiovascular mortality, major bleeding, and worsening heart failure, indicating a need for improved AF management in these settings.
Background: The extent to which differences in results from Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) and Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial (ROCKET) atrial fibrillation (AF)-the landmark trials for the approval of apixaban and rivaroxaban, respectively, for non-valvular AF-were influenced by differences in their protocols is debated. The potential influence of selection criteria on trial results was assessed by emulating these trials in data from the Global Anticoagulant Registry in the Field (GARFIELD)-AF registry.
Methods: Vitamin K antagonist (VKA) and non-vitamin K oral antagonist (NOAC) users from GARFIELD-AF were selected according to eligibility for the original ARISTOTLE or ROCKET AF trials.
Article Synopsis
- A medical examiner system was implemented in England and Wales in 2019 to improve how cases are reported to HM Coroner (HMC), and a study evaluated its impact by comparing notifications from a hospital in 2018 and 2022.
- The findings reveal a significant decrease in overall HMC notifications from 25.3% in 2018 to 17.6% in 2022, particularly for deaths related to medical treatments, while notifications related to neglect increased from 3.3% to 12.2%.
- Additionally, there was an uptick in post-mortem examinations and inquests, indicating a shift toward more appropriate notifications and outcomes, along with a reduction in cases resulting in 'no